-+ 0.00%
-+ 0.00%
-+ 0.00%
Keenova Announces Two New TERLIVAZ® (terlipressin) Analyses at The Liver Meeting®
Share
Listen to the news

DUBLIN, Nov. 5, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two new presentations highlighting clinical trial and real-world evidence related to TERLIVAZ® (terlipressin) in treating hepatorenal syndrome-acute kidney injury (HRS-AKI) will be presented at The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-8, 2026.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending